Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease

NCT07151378 is registered in ClinicalTrials.gov with University Hospital Tuebingen as lead sponsor.

NCT NCT07151378
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07151378 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Intestinal Levodopa + Entacapone Therapy (Lecigon®) to Counteract Dopaminergic Desensitization and Neuropsychiatric Complications in Parkinson's Disease
Lead sponsor
University Hospital Tuebingen
Phase
Phase 3
Overall status
Recruiting
Start date
October 27, 2025
Completion date
September 22, 2030
Enrollment
150 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease (disorder)